- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Groups Join ACA Defense; Stem Cell Treatments; Measles Surge
The American Medical Association and the AARP issue briefs in defense of the Affordable Care Act (ACA), while President Trump is delaying an ACA alternative until after the 2020; top hospitals offer unproven stem cell treatments; the measles outbreak hits a new high.
AMA, AARP Defend ACA While Trump Reportedly Punting ACA Alternative to 2020
The American Medical Association (AMA) and the AARP (formerly the American Association of Retired Persons) filed amicus briefs in the case of Texas v. United States, according to statements from the AMA and the AARP. Meanwhile, President Trump is delaying an ACA alternative until after the 2020 election, according to The New York Times.
Unproven Stem Cell Treatments on the Rise in Best Hospitals
A growing number of well-regarded hospitals are pursuing stem cell treatments and related therapies such as platelet injections, reported Kaiser Health News. The treatments, aimed at treating joint pain without surgery,include injecting patients’ joints with their own fat or bone marrow cells. However, the evidence supporting the costly therapies has been lacking, Kaiser said.
Reported Cases of Measles Reach New High
More people have contracted measles in the first 3 months of 2019 than throughout the entire year of 2018, The Washington Post reported. This year marks the second highest number of cases reported since US health officials declared the disease “eliminated” 19 years ago. There have been a total of 387 cases reported, spurring from a decrease in child immunizations as a result of from misinformation about the safety of vaccines.
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
